Alan G. Zimmermann

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Mark Lakshmanan, Brian Rayner, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2018 · 635 citations

Medicine, Endocrinology, Pharmacotherapy +11

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Francesco Giorgino, Marian Benroubi, Jui‐Hung Sun et al. · Diabetes Care · 2015 · 261 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement

Andrea Attanasio, Daojun Mo, Eva Marie Erfurth et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 115 citations · Full text

Veterinary Medicine, Endocrinology, Metabolic Physiology +12

GH Treatment to Final Height Produces Similar Height Gains in Patients With SHOX Deficiency and Turner Syndrome: Results of a Multicenter Trial

Werner Blum, Judith L. Ross, Alan G. Zimmermann et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 102 citations · Full text

Medicine, Endocrinology, Pediatrics +17

Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients

Mark L. Hartman, Rong Xu, Brenda Crowe et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 88 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +13